# Merck pipeline

## Phase I

- **berzosertib (M6620)**
  - ATR inhibitor
  - Solid tumors

- **peposertib (M3814)**
  - DNA-PK inhibitor
  - Solid tumors

- **M1774**
  - ATR inhibitor
  - Solid tumors

- **M3258**
  - LMP7 inhibitor
  - Multiple myeloma

- **M4344**
  - ATR inhibitor
  - Solid tumors

- **M8891**
  - MetAP2 inhibitor
  - Solid tumors

## Phase II

- **peposertib (M3814)**
  - DNA-PK inhibitor
  - Rectal cancer

- **tepotinib**
  - MET kinase inhibitor
  - Non-small cell lung cancer, ME7ex14 skipping

- **tepotinib**
  - MET kinase inhibitor
  - Non-small cell lung cancer, MET amplified

- **bintrafusp alfa**
  - TGFbeta trap/anti-PD-L1
  - Cervical cancer 1L

- **bintrafusp alfa**
  - TGFbeta trap/anti-PD-L1
  - Small cell lung cancer 1L/2L

- **bintrafusp alfa**
  - TGFbeta trap/anti-PD-L1
  - Biliary tract cancer 1L

- **bintrafusp alfa**
  - TGFbeta trap/anti-PD-L1
  - Rectal cancer

- **bintrafusp alfa**
  - TGFbeta trap/anti-PD-L1
  - Cervical cancer 2L

## Phase III

- **avelumab**
  - anti-PD-L1 mAb
  - Solid tumors

- **avelumab**
  - anti-PD-L1 mAb
  - Non-small cell lung cancer

- **avelumab**
  - anti-PD-L1 mAb
  - Urothelial cancer

- **atacicept**
  - anti-BlyS/APRIL fusion protein
  - Systemic lupus erythematosus

- **atacicept**
  - anti-BlyS/APRIL fusion protein
  - IgA nephropathy

- **sonelokimab (M1095)**
  - anti-IL-17 A/F nanobody
  - Psoriasis

- **sprifermin**
  - fibroblast growth factor 18
  - Osteoarthritis

- **M5049**
  - TLR7/8 antagonist
  - Malaria

## Registration

- **tepotinib**
  - MET kinase inhibitor
  - Non-small cell lung cancer, ME7ex14 skipping

- **avelumab**
  - anti-PD-L1 mAb
  - Urothelial cancer 1L-M

## Program under out-licensing agreement

- Oncology
- Immuno-Oncology
- Immunology
- Neurology
- Global Health
- Program under out-licensing agreement

---

1L, first-line treatment; 1L-M, first-line maintenance treatment; 2L, second-line treatment.

1 Includes studies (phase I/II) in collaboration with NCI.
2 Includes studies in combination with avelumab.
3 Includes study in combination with bintrafusp alfa.
4 As announced on October 06 2020, Merck has entered into an out-licensing agreement with Novartis.
5 In combination with osimertinib in MET amplified, advanced or metastatic NSCLC harboring activating EGFR mutations.
6 Avelumab combination studies with talazoparib, axitinib, ALK inhibitors, cetuximab, or chemotherapy.
7 Pending Phase III initiation in 2021.
8 As announced on August 25 2020, the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the new drug application (NDA) in non-small cell lung cancer (NSCLC).
9 As announced on June 22 2020, the European Medicines Agency (EMA) has validated for review the Type II variation application for avelumab for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC).

Unless noted otherwise, clinical programs conducted in collaboration with external partners are not shown unless Merck is the sponsor of that respective trial.